you are here: Home News Mylan

Mylan

Pfizer shares rise by 7% after marketing and sale pact with Mylan for two neuro therapy brands
Biocon's arm to acquire Viatris’ biosimilars for $3.3 billion
Exclusive | Biocon in talks with Mylan to merge biosimilar businesses, plans IPO after merger: Sources
Lupin: Covid opportunity strengthens US business
FDA issues warning Letter to Mylan's Telangana plant; Company says no impact
COVID-19 treatment | Mylan launches generic version of Remdesivir in India
Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall
Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA
USFDA pulls up Mylan for manufacturing violations at Andhra plant
Mylan to invest $1 billion in India on capex in 6 years
Corporate Corridor | Pfizer’s Upjohn and Mylan combining forces holds lessons for Indian pharma majors
Dr Reddy’s Suboxone launch: Why investors shrugged it off
Mylan recalls 1.2 mn bottles of 'made in India' BP drug from US due to cancer risk
Mylan to commercialise Lupin's etanercept biosimilar
We expect roll out of insulin glargine in Europe to start in second half of 2018, says Biocon
Biocon, Mylan get European Commission nod to market biosimilar insulin glargine
Biocon gets Europe and Australia approval to sell insulin glargine
Partnership with Sandoz is for the future wave of biosimilars: Biocon
Mylan surges, Teva slumps after FDA approves Copaxone copy
FDA nod to Natco's marketing partner Mylan for generic Copaxone
Pharma major Mylan puts Andhra Pradesh plant on sale
India's antitrust watchdog orders probe into Roche cancer drug
USFDA issues warning letter to Mylan for Nashik facility
EU regulator recommends suspending 300 drugs tested by Indian CRO firm
Analysts cheer Mylan-Roche settlement, upbeat on Biocon

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Mylan

Pfizer shares rise by 7% after marketing and sale pact with Mylan for two neuro therapy brands

Biocon's arm to acquire Viatris’ biosimilars for $3.3 billion

Exclusive | Biocon in talks with Mylan to merge biosimilar businesses, plans IPO after merger: Sources

Lupin: Covid opportunity strengthens US business

FDA issues warning Letter to Mylan's Telangana plant; Company says no impact

COVID-19 treatment | Mylan launches generic version of Remdesivir in India

Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall

Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA

USFDA pulls up Mylan for manufacturing violations at Andhra plant

Mylan to invest $1 billion in India on capex in 6 years

Corporate Corridor | Pfizer’s Upjohn and Mylan combining forces holds lessons for Indian pharma majors

Dr Reddy’s Suboxone launch: Why investors shrugged it off

Mylan recalls 1.2 mn bottles of 'made in India' BP drug from US due to cancer risk

Mylan to commercialise Lupin's etanercept biosimilar

We expect roll out of insulin glargine in Europe to start in second half of 2018, says Biocon

Biocon, Mylan get European Commission nod to market biosimilar insulin glargine

Biocon gets Europe and Australia approval to sell insulin glargine

Partnership with Sandoz is for the future wave of biosimilars: Biocon

Mylan surges, Teva slumps after FDA approves Copaxone copy

FDA nod to Natco's marketing partner Mylan for generic Copaxone

Pharma major Mylan puts Andhra Pradesh plant on sale

India's antitrust watchdog orders probe into Roche cancer drug

USFDA issues warning letter to Mylan for Nashik facility

EU regulator recommends suspending 300 drugs tested by Indian CRO firm

Analysts cheer Mylan-Roche settlement, upbeat on Biocon